This program is intended for rheumatologists, nephrologists, primary care physicians, nurse practitioners, and other healthcare professionals who care for patients with SLE.
Upon completion of this activity, participants should be able to:
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Karen H. Costenbader, MD, MPH
Professor of Medicine
Department of Medicine
Harvard Medical School
Director, Lupus Program
Division of Rheumatology, Inflammation and Immunity
Brigham and Womens Hospital
Karen H. Costenbader, MD, MPH, has disclosed that she has received funds for research support from Exagen, Gilead Sciences, and Merck and consulting fees from Amgen, AstraZeneca, GlaxoSmithKline, Janssen, and Lilly.
Brad H. Rovin, MD
Professor and Director, Division of Nephrology
The Lee A. Hebert Professor of Nephrology
Medical Director, The Ohio State Center for Clinical Research Management
The Ohio State University Wexner Medical Center
Brad H. Rovin, MD, FASN, FACP, has disclosed that he has received funds for research support from Aurinia, BioCryst, Biogen Idec, Bristol-Myers Squibb, Calliditas, ChemoCentryx, Human Genome Sciences, Idorsia, and Lucin and consulting fees from Admirx, Alexion, AstraZeneca, Aurinia, BioCryst, Biogen Idec, Bristol-Myers Squibb, Calliditas, Chugai, Corrona, EMD Serono, Genentech/Hoffmann-La Roche, Janssen, Kezar Life Sciences, Lilly, MorphoSys, Novartis, Omeros, Otsuka, Pfizer, Principia, and Travere.
Vice President, Managing Scientific Director
Craig Borders has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Petra Cravens, PhD
Petra Cravens, PhD, has no relevant conflicts of interest to report.
Kristen Morrow, PhD
Kristen Morrow, PhD, has no relevant conflicts of interest to report.
Jennifer Simpson, DNP
Jennifer Simpson, DNP, has disclosed that she has received speaker fees from AbbVie and Janssen; and has served on the advisory board for Amgen and AstraZeneca.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 25, 2022, through May 24, 2023:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
This program has been made available online.
The goal of this initiative is to improve the knowledge and competence of learners in rheumatology and nephrology settings regarding the management of SLE and LN, including the management of patients with SLE/LN affected by health disparities.